Literature DB >> 12093659

Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up.

Rajiv Bindlish1, Garry P Condon, James D Schlosser, Joyce D'Antonio, Karen B Lauer, Richard Lehrer.   

Abstract

PURPOSE: To examine the 5-year complications and results of primary trabeculectomy with mitomycin-C (MMC).
DESIGN: Retrospective, noncomparative interventional case series. PARTICIPANTS: One hundred twenty-three eyes that underwent primary trabeculectomy with MMC between December 1991 and March 1995.
METHODS: All patients received standard trabeculectomy performed by one of two surgeons, using a Weck cell-soaked pledget of MMC, 0.25, 0.33, or 0.5 mg/ml, for 0.5 to 5 minutes. Laser suture lysis was performed postoperatively for intraocular pressure control. MAIN OUTCOME MEASURES: The incidence of complications, including hypotony with or without maculopathy, bleb leak or blebitis, pressure control, and medication reduction at yearly intervals.
RESULTS: Mean preoperative and year 5 postoperative intraocular pressures (IOP) were 25.79 and 9.91 mmHg (P < 0.05, paired t test). Hypotony (IOP < 6) occurred in 42.2% of eyes after a mean follow-up of 26.1 months. Hypotony maculopathy occurred in 8.9% of eyes at mean follow-up of 33.7 months. Bleb leak occurred in 14.6% of eyes at a mean follow-up of 27.9 months. Blebitis occurred in 5.7% of eyes at a mean follow-up of 35.4 months, and endophthalmitis occurred in 0.8% of eyes at 15 months; 14.9% of eyes lost 4 lines of visual acuity. The single predictor for the development of late-term hypotony was IOP 1 month after operation (P < 0.05).
CONCLUSIONS: Primary mitomycin trabeculectomy significantly lowers IOP at 5 years but is associated with a high incidence of delayed hypotony.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093659     DOI: 10.1016/s0161-6420(02)01069-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  77 in total

1.  Postoperative fibrosis suppression.

Authors:  A L Schwartz
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

2.  Trabeculectomy and antimetabolites.

Authors:  S Fraser
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

3.  [Canaloplasty. A new way in glaucoma surgery?].

Authors:  N Körber
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

4.  Building a safer trabeculectomy.

Authors:  S Lin
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

5.  Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor.

Authors:  Thomas G McCauley; Jeffrey C Kurz; Patricia G Merlino; Scott D Lewis; Madaline Gilbert; David M Epstein; H Nicholas Marsh
Journal:  Pharm Res       Date:  2006-01-19       Impact factor: 4.200

6.  Improved retinal function after trabeculectomy in glaucoma patients.

Authors:  Elisabeth Wittström; Patrik Schatz; Monica Lövestam-Adrian; Vesna Ponjavic; Anders Bergström; Sten Andréasson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-29       Impact factor: 3.117

7.  Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts.

Authors:  Xuan Wang; Ya-Zhi Fan; Liang Yao; Jian-Ming Wang
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

8.  Different modes of intraocular pressure reduction after three different nonfiltering surgeries and trabeculectomy.

Authors:  Etsuo Chihara; Ken Hayashi
Journal:  Jpn J Ophthalmol       Date:  2011-03-13       Impact factor: 2.447

9.  A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis).

Authors:  Mark Brian Sherwood
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Risk of endophthalmitis and other long-term complications of trabeculectomy in the Collaborative Initial Glaucoma Treatment Study (CIGTS).

Authors:  Sarwar Zahid; David C Musch; Leslie M Niziol; Paul R Lichter
Journal:  Am J Ophthalmol       Date:  2012-12-13       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.